DBL™ Ephedrine Sulfate

국가: 뉴질랜드

언어: 영어

출처: Medsafe (Medicines Safety Authority)

지금 구매하세요

제품 특성 요약 제품 특성 요약 (SPC)
04-01-2021

유효 성분:

Ephedrine sulfate 30 mg/mL

제공처:

Pfizer New Zealand Limited

INN (International Name):

Ephedrine sulfate 30 mg/mL

복용량:

30 mg/mL

약제 형태:

Solution for injection

구성:

Active: Ephedrine sulfate 30 mg/mL Excipient: Sodium chloride Water for injection

패키지 단위:

Ampoule, glass, 5 x 1mL, 5 dose units

수업:

Class B2 Controlled Drug

처방전 유형:

Class B2 Controlled Drug

Manufactured by:

Siegfried PharmaChemikalien Minden GmbH

제품 요약:

Package - Contents - Shelf Life: Ampoule, glass, 1mL - 5 dose units - 36 months from date of manufacture stored at or below 25°C - Ampoule, glass, 1mL - 10 dose units - 36 months from date of manufacture stored at or below 25°C

승인 날짜:

1984-03-08

제품 특성 요약

                                Hosp 7.0
Page 1 of 8
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
_ _
DBL
™
Ephedrine Sulfate Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
DBL
™
Ephedrine Sulfate Injection is a sterile solution of Ephedrine Sulfate
in Water for
Injections. Each mL contains 30 mg of Ephedrine Sulfate and 3 mg of
Sodium Chloride in
Water for Injections.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
DBL
™
Ephedrine Sulfate Injection is a sterile solution for injection
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
DBL
™
Ephedrine Sulfate Injection is indicated in the treatment of shock
unresponsive to
fluid replacement. It is also indicated in the treatment of
hypotension secondary to spinal
anaesthesia. DBL
™
Ephedrine Sulfate Injection has also been used in the treatment of
bronchial
asthma
and
reversible
bronchospasm
although
more
selective
agents
(beta-
adrenergic agonists) are now available.
4.2 DOSE AND METHOD OF ADMINISTRATION
DBL
™
Ephedrine Sulfate Injection is administered by the intramuscular,
subcutaneous or
intravenous route. Patients in shock may require intravenous
administration to ensure
absorption of the drug. When administered intravenously, the injection
should be given
slowly. Care should be taken to avoid extravasation, since this may
result in tissue necrosis
and sloughing. Ephedrine sulfate should be administered in the lowest
effective dose. The
parenteral adult dose should not exceed 150 mg in 24 hours.
As a pressor:
_Adult dose:_ The usual adult dose is 25-50 mg (range 10-50 mg)
administered intramuscularly
or subcutaneously. Additional doses should be based on patient
response. The intravenous
route may be used if an immediate response is required. The dosage for
the intravenous route
is 10-25 mg which may be repeated every 5-10 minute until the desired
response is obtained.
_Paediatric dose:_ The recommended paediatric dose is 3 mg/kg/day or
100 mg/m
2
/day via the
intravenous or subcutaneous route, given in 4-6 divided doses.
Hosp 7.0
Page 2 of 8
During th
                                
                                전체 문서 읽기